The USFDA had conducted the inspection from 17 October 2022 to 21 October 2022 at company's Bioequivalence facility at Vadodara.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

The pharmaceutical company reported a consolidated net loss of Rs 65.88 crore in Q1 FY23 as against a net profit of Rs 164.52 crore posted in Q1 FY22. Net sales fell 4.8% year on year to Rs 1,262.14 crore in the quarter ended 30 June 2022.

Shares of Alembic Pharmaceuticals were up 0.17% to Rs 549.60 on the BSE.